The TRANSFIGURE study of 198 patients with significant nail psoriasis showed that Costentyx was superior to placebo at Week 16 in mean improvement (decrease) in the Nail Psoriasis Severity Index (NAPSI) compared to baseline (-45.3% vs. -10.8%; P<0.0001) .



Continue Reading